NEXR
Nexera Technologies Ltd
NASDAQ · Healthcare · Biotechnology · IL
$1.70
−4.49%Year over year
Reported trailing growth
- Revenue
- +74.2%
- EBITDA
- —
- EBIT
- —
- EPS
- +98.0%
- Free cash flow
- +26.4%
- Operating cash flow
- +27.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +42.2%
- EBITDA
- +7.6%
- EBIT
- -19.1%
- Net income
- +52.9%
- EPS
- +97.1%
- Free cash flow
- -1.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026